Kornimate/medical-research-clean huggingface dataset:
evaluating validity of ultrasonography in determining distal radius fracture reduction

Conditions: Distal Radius Fracture

Summary: the purpose of this study is to evaluate whether ultrasonography guidance compare with the simple radiography aids in determining the adequacy of distal radius fracture reduction.

distal radius fracture is one of the most common causes for visiting the emergency department. nowadays, simple radiography is used as a control standard for evaluating reduction of distal radius fractures. the disadvantages include time wasting, frequent x-ray exposures and use of more sedation in determining adequate reduction, made scientists to evaluate alternative method such as ultrasonography which fast, easy and less dangerous were considered as advantages. the investigators goal was to identify whether ultrasonography guidance compare with the simple radiography aids in determining the adequacy of distal radius fracture reduction.

Eligibility criteria:
inclusion criteria: * \> 21 years old and a diagnosing of a distal radius fracture based on simple radiography. exclusion criteria: * open fractures * more than 20 degree angulation * joint internal involvement, communicated and along with neurovascular compromised fractures * patient's surgery due to other causes * need to stay in the icu and not being able to be treated at the same time for distal radius fracture * patient's refusal to participate in the study

Keywords: radius fracture sensitivity reduction adequacy
continuous glucose monitoring for emergency laparotomy

Conditions: Peritonitis; Surgical Site Infection; Infections; Hyperglycemia; Hypoglycemia

Summary: clue trial aims to determine the feasibility and predictive value for surgical site infection (ssi) of continuous glucose monitoring (cgm) in emergency laparotomy patients with diffuse peritonitis.

hyperglycaemia commonly occurs during surgery due to a reaction to metabolic stress and trauma. it has been shown that improper glycemia control leads to impaired wound healing and a higher risk of other postoperative complications. therefore, the investigators predict that number of hyperglycaemia episodes could be a predictor of ssi. continuous glucose monitoring allows for a minimally invasive real-time remote glycemia control, yet it has not been applied in an emergency surgery setting. intraoperative glycemia monitoring would allow to determine the effect of specific interventions during a surgical procedure that may provoke hyperglycaemia. clue is a single-centre prospective observational study held in an academic tertiary medical centre in poland. adult patients qualified for an emergency laparotomy for peritonitis in university clinical centre (ucc) division of oncological, endocrine and general surgery, with class ≥ iii wounds according to centers for disease control and prevention (cdc) classification, will be eligible for the clue trial. patients who will be unable or will refuse to express informed consent will be excluded. patients will be co-enrolled in pristine randomized health services study that aims to compare the effectiveness of negative pressure wound therapy (npwt) and primary closure (pc) in surgical site infection prevention. on admission day, patients will have a dexcom g6 system placed on the outer part of the upper arm. patients will undergo standard surgical procedures and perioperative care. patients will be randomized to npwt or pc according to pristine protocol. glycemia will be continuously monitored for 10 days.

Eligibility criteria:
inclusion criteria: * emergency laparotomy for peritonitis * written informed consent exclusion criteria: - open abdomen treatment

Keywords: continuous glucose monitoring cgm dexcom g6
low load, high gains: blood flow restriction's impact on quadriceps adaptations

Conditions: Healthy Individuals

Summary: low-load resistance exercise with blood flow restriction (bfr-re) presents a compelling alternative to high-load resistance exercise (hl-re), particularly in scenarios where high loads are not feasible due to various limitations. blood flow restriction exercise restricts blood flow to the working muscle, creating a state of ischemia. a significant advantage of bfr-re lies in its capacity to stimulate muscle hypertrophy and strength adaptations using light external loads (20-30% 1rm), comparable to those achieved with high-load (hl) training programs that employ 70-85% 1rm as a result, bfr training has been increasingly adopted in both athletic performance and rehabilitation settings over the past few decades. quadriceps strength and power are essential factors in both the advancement of athletic performance and the successful return to unrestricted sporting activity following injury. the findings of culvenor et al.'s review strongly suggest that weakened quadriceps strength is a significant risk factor for symptomatic and functional decline in the knee during both activities of daily living and sport-recreational activities. numerous electromyographic (emg) findings suggest that single-joint and multijoint exercises elicit varying muscle activation patterns. for instance, single-joint exercises targeting the quadriceps, such as leg extensions, demonstrate higher emg amplitudes compared to multijoint lower-extremity exercises like leg presses and squats. resistance training, characterized by the application of high mechanical tension, remains the cornerstone for promoting muscle hypertrophy, so, research suggests that higher training intensities are associated with greater hypertrophy, up to a certain point. while both light and heavy loads have been shown to elicit similar muscle growth when sets are taken to failure. studies have reported that high-repetition training with light loads leads to greater central fatigue. existing literature comparing the effects of bfr-re and hl-re primarily focuses on the some quadriceps and hamstring muscle group and its associated exercises. however, none of these studies employed a training protocol in which sets were taken to or near failure.


Eligibility criteria:
inclusion criteria: * keep healthy * must be able to attend training regularly exclusion criteria: * smoking habit * had orthopedic conditions that hindered lower-body resistance exercise, had hypertension (140/90 mm hg), or had a bmi exceeding 30 kg/m2

Keywords: vascular occlusion shear wave elastography hypertrophy muscle stiffness strength
iort after surgical resection of brain metastases

Conditions: Brain Neoplasms

Summary: to evaluate the feasibility and efficacy of the intraoperative radiation therapy (iort) after the resection of a brain metastases to reduce the incidence of local relapse


Eligibility criteria:
inclusion criteria: * age ≥ 18 years, karnofsky performance index ≥ 70. * newly diagnosed cerebral or cerebellar lesion (contrast enhancing on a t1- weighted mri scan) amenable to total resection with no dural attachment. * frozen section confirming a metastasis of an extracranial (i.e. non-cns) tumor. * adequate distance to optic nerve(s), chiasm and brainstem (organs at risk for radiotherapy). * adequate birth control. * informed consent. exclusion criteria: * leptomeningeal spread and dural attachment (assessed pre- and intraoperative). * frozen section reveals primary cns tumor, lymphoma, sclc or germinoma. * psychiatric or social condition potentially interfering with compliance. * contraindication against anesthesia, surgery, mri and/or contrast agents. * pregnant or breast-feeding women.

Keywords: brain metastases neurosurgery intraoperative radiotherapy local therapy
light therapy for bipolar disorder. efficacy of light therapy for bipolar depression: a randomized controlled trial

Conditions: Bipolar Disorder; Major Depressive Episode

Summary: the purpose of this study is to understand the efficacy of light therapy for bipolar depression.

bipolar disorders (bd) are associated with chronic depression, disability, and increased suicide risk. building on earlier findings, we conducted a 6-week randomized, double-blind, placebo-controlled trial to investigate the efficacy of midday light therapy for bipolar depression. the aims were to examine the change in depression levels and the proportion of patients who responded and remitted. we assessed predictors of response with measures of side effects, sleep quality, suicidality, and psychosocial functioning. we included depressed adults with bd-type i or ii confirmed on the scid interview and taking stable-dosed antimanic medication. we excluded patients with psychosis, rapid cycling, obsessive compulsive disorder, alcohol or substance use disorders, hypomania or mania, and severe suicidality. patients were randomized to 7000 lux broad spectrum light therapy or 50 lux dim red light for 45-60 minutes daily. weekly, the blinded-clinician assessed symptoms with the structured interview guide for the hamilton depression scale with atypical depression supplement (sigh-ads) and global functioning.

Eligibility criteria:
inclusion criteria: * ages 18-65 years * dsm-iv criteria bd i or ii depressive episode, * sigh-ads \>20; duration \>2 weeks. * stable dose antidepressant drug \>8 weeks with concurrent antimanic drug * controlled thyroid disease * subjects with preexisting eye diseases will be included. * able to provide informed consent * stable minimum dose antimanic drug \>4weeks: lithium 0.5 meq/l, divalproex na 50 mcg/ml, olanzapine 5mg daily, carbamazepine 4mg/l; lamotrigine 100mg daily, risperidone 2mg daily, quetiapine 400 mg daily, ziprasidone 10 mg bid, and aripiprazole 5 mg qd. * stable unchanged psychotherapy for \>16weeks exclusion criteria: * the following eye diseases: retinal disease, cataract surgery and lens removal, macular degeneration, * taking photosensitizing drugs such as phenothiazines (chlorpromazine), antimalarial drugs, melatonin and hypericum. * acute psychosis (dsm-iv criteria) * rapid cycling in the past 1 year * obsessive compulsive disorder * alcohol or substance abuse or dependence in the past 6 months. * mrs\>5 * recent history of a suicide attempt (3 months) or active suicidal ideation (sighads item h11 \>2) * beta-adrenergic blockers, exogenous melatonin, chronic nsaids

Keywords: bipolar disorder depression midday light therapy bipolar disorder type i or ii
covid-19 infection in cancer pantients

Conditions: Covid19

Summary: it's an obsevational retrospective/prospective study. analyzing the evolution of covid 19 infection in cancer patients can provide interesting information in the management of these patients. for this reason, the purpose of this study is to implement a registry to describe and monitor cancer patients affected by covid 19, the factors that are associated with an unfavorable evolution, to develop a strategy for the risk assessment of these patients and recommendations. relating to their treatment. particular attention will be paid to patients suffering from urological tumors because the treatment followed by the patients would seem to expose them to a greater risk when they are infected with coronavirus, furthermore, from the literature it is clear that there may be a connection between sex hormones and ace2 levels in the plasma. in fact, the estrons up-regulate the concentration of ace2 in the circulation and this could be the reason why women would seem more protected than men once they contract the coronavirus infection

primary objectives: * describe cancer patients with covid-19 and their clinical course; * identify predictors of the most severe clinical course; * identify prognostic factors; secondary objectives * monitor patients with urological tumors with particular attention; * dosing parameters of inflammation such as il-6 and ifnα; * measure the ace2 levels. patients with oncological pathology who contracted covid 19 infection from january 1, 2020 until the who declaration of the end of the pandemic will be studied.

Eligibility criteria:
inclusion criteria: * confirmation of covid-19 in the laboratory (rt-pcr techniques); * suspected cases of covid-19; clinically diagnosed based on symptoms (fever\> 37.5 °, decrease in oximeter saturation by at least 5%, cough, diarrhea, otitis, dysgeusia, myalgia, arthralgia, conjunctivitis and rhinorrhea) + close contact a covid-19 subject positive; * asymptomatic cases; diagnosed based on positive swab results but without symptoms even dead patients exclusion criteria: -

Keywords: covid-19 oncological patients cancer coronavirus infection disease
xerecept intravenous dose escalation in japanese and caucasian volunteers

Conditions: Edema

Summary: 1. to investigate the safety and tolerability of xerecept during and following a 24-hour intravenous administration to healthy japanese to healthy japanese and caucasian subjects 2. to compare the pk profile of hcrf during and following a 24-hour intravenous xerecept administration between healthy japanese and caucasian subjects

none needed

Eligibility criteria:
inclusion criteria: * healthy male and female japanese subjects who are citizens of japan * healthy male and female caucasian subjects * age range 20-45 years * bmi \>19 and \<27 kg/m squared exclusion criteria: * female subjects must not be pregnant at the time of study and use adequate birth control methods before,during and 4 weeks after the study * subjects must be negative for hcv and hiv * subjects must have negative urine tests for drugs of abuse and alcohol at screening * subjects must not have any clinically significant medical conditions

Keywords: xerecept pharmacokinetics japanese versus caucasians
a study of ak129 with or without ak117 in pd(l)1-refractory classic hodgkin lymphoma

Conditions: Classic Hodgkin Lymphoma

Summary: this is a phase i/ii study. all subjects are patients diagnosed with relapse or refractory (r/r) classic hodgkin lymphoma (chl) and has progressed on treatment with pd-1/l1 inhibitor therapy. the purpose of this study is to evaluate the safety and efficacy of ak129 (bispecific antibody targeting lag-3 and pd-1) monotherapy or in combination with ak117 (anti-cd47 monoclonal antibody) in r/r chl with pd-1/l1 inhibitor treatment failure.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years old at the time of enrolment. * eastern cooperative oncology group (ecog) performance status of 0 or 1. * expected survival of ≥ 12 weeks. * diagnosed as r/r chl according to lugano 2014 criteria. * has progressed on treatment with pd-1/l1 inhibitior therapy. * has adequate organ function. * all female and male subjects of reproductive potential must agree to use an effective method of contraception from the start of screening until 120 days after the last dose of study treatment. exclusion criteria: * diagnosed with nodular lymphocyte-predominant hodgkin lymphoma (nlphl) or gray zone lymphoma. * central nervous system (cns) lymphoma involvement. * known history of human t-cell leukemia virus type 1 (htlv-1) infection. * autologous hematopoietic stem cell transplantation (auto-hsct) or chimeric antigen receptor t cell immunotherapy (car-t) within 90 days prior to the first dose of study treatment. * known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation (allo-hsct). * previous use of any agents targeting the cd47-sirpα pathway, lag-3 pathway, or similar targets. * has other malignancies within 3 years prior to the first dose or residual lesions from other malignancies diagnosed more than 3 years ago. * has an active autoimmune disease requiring systemic treatment within 2 years prior to the first dose. * history of active or previously confirmed inflammatory bowel disease. * history of interstitial lung disease requiring corticosteroid therapy, or current interstitial lung disease. * has known active hepatitis b or hepatitis c. * unresolved toxicity from previous anti-tumor treatment. * uncontrolled comorbidities.
pharmacokinetics, pharmacodynamics and safety of shr4640 in patients with hepatic impairment

Conditions: Hepatic Impairment

Summary: study to evaluate pharmacokinetics, pharmacodynamics and safety of shr4640 in patients with mild, moderate hepatic impairment and normal liver function in phase i clinical study.


Eligibility criteria:
inclusion criteria: - all subjects: * signing the informed consent forms. * 18 years to 65 years (inclusive). * body mass index should be between 18 and 30 kg/m2 (inclusive). * no medication was used before screening#or stable medication for 4 weeks. normal liver function: • clinical laboratory tests during the screening period were normal or the abnormality has no clinical significance. hepatic impaired subjects: * child-pugh classification score clinically determined as mild or moderate hepatic impairment. * liver damage due to primary liver disease. exclusion criteria: - all subjects: • subject known or suspected of being sensitive to the study drugs or its ingredient. normal liver function: * previous history of liver function impairment, or physical examination and laboratory examination at screening indicated the presence or possibility of liver function impairment. * hepatitis b surface antigen (hbsag) positive or anti-hepatitis c virus (hcv) antibody or hepatitis c core antigen positive within 3 months prior to administration. hepatic impaired subjects: * suspected or diagnosed as liver cancer or with other malignant tumors. * drug induced liver injury#acute liver injury#liver transplantation history. * subjects with hepatic failure,or severe complications caused by hepatocirrhosis.
analgesia during pediatric digestive endoscopy: a comparison of two protocols for procedural sedation

Conditions: Pain

Summary: the purpose of this study is to determine whether ketamine, midazolam, and meperidine are more effective than midazolam and meperidine alone for procedural sedation and analgesia in pediatric digestive endoscopy. secondary outcomes are the incidence of cardiorespiratory side effects and the necessity of rescue doses.

90 patients will be included. the sedation will include 0.1mg/kg, max 5mg iv of midazolam, 1mg/kg, max 50mg iv of meperidine, and placebo (0.9%nacl) or ketamine 0.5mg/kg iv. rescue doses will be given as usual, using meperidine and or midazolam 50% of the initial dose.

Eligibility criteria:
inclusion criteria: * children =/\> 10 years of age * undergoing elective diagnostic colonoscopy * asa score class 1-3. exclusion criteria: * children younger than 10 years of age * known epilepsy under treatment * asa score class 4 or more * interventional colonoscopy (e.g.polypectomy)

Keywords: pediatric gastroscopy colonoscopy sedation ketamine
evaluation of neuroma perfusion with indocyanine green fluorescence angiography

Conditions: Neuroma; Neuroma Amputation; Neuroma of Upper Limb; Neuroma of Lower Limb

Summary: the purpose of this study is to characterize the perfusion of neuromas using indocyanine green fluorescence angiography

neuromas represent the frustrated regeneration of injured nerve axons encased in a bulbous scar. symptomatic neuromas are particularly problematic in patients with amputations. targeted muscle reinnervation is a novel surgical approach to neuroma treatment, resulting in improved residual limb pain in amputees. nevertheless, a subset of targeted muscle reinnervation patients achieve inadequate relief. incomplete neuroma excision may be of particular concern in such cases, as failure to completely excise the neuroma risks leaving a scarred proximal nerve stump behind. despite the critical importance of complete neuroma excision, there is no clear definition of a neuroma's "zone of injury". indeed, intraoperatively determining where to cut a nerve to ensure accurate and complete excision of a neuroma at the time of reconstruction or repair is an unsolved problem in peripheral nerve surgery. the proposed research aims to characterize the perfusion of neuromas using fluorescence angiography. specifically, we will test the hypothesis that intravascular indocyanine green (icg) renders visible the perturbations in nerve perfusion associated with neuromas, and that these altered perfusion patterns correlate with the nerve's "zone of injury" as identified by histopathology. ultimately, indocyanine green (icg) fluorescence angiography may facilitate intraoperative decision-making at the time of neuroma excision.

Eligibility criteria:
inclusion criteria: * age \> 18 years * clinical diagnosis of neuroma * scheduled elective surgery for neuroma excision exclusion criteria: * minors, or age \< 18 years old at the time of surgery * unable to provide written, informed consent * prisoners and decision-impaired individuals * pregnant or lactating women * history of allergy to indocyanine green * history of allergy to iodides * history of allergic asthma * history of hepatic failure * history of renal failure * patients in whom the planned surgical incision/approach does not include excision of the neuroma * patients in whom adequate surgical exposure of the neuroma is unable to be obtained, as determined intraoperatively at the time of surgery by the investigator or co-investigators * any subject who, at the discretion of the investigator or co-investigators, is not suitable for inclusion in the study

Keywords: neuroma indocyanine green targeted muscle reinnervation regenerative peripheral nerve interface nerve repair fluorescence angiography
effects of magnesium on individuals undergoing coronary artery bypass graft surgery

Conditions: Coronary Disease; Heart Diseases; Cardiovascular Diseases; Neurologic Manifestations

Summary: the purpose of this study is to examine the effects of supplemental magnesium on the neurocognitive function of individuals undergoing coronary artery bypass graft (cabg) surgery.

background: approximately 400,000 individuals undergo heart operations each year and cognitive impairment occurs frequently following surgery. an increasing number of these individuals are elderly and are particularly susceptible to cognitive dysfunction following surgery. cognitive impairment is most notable in the early stages following heart surgery, but it may persist in some individuals. while many people think cognitive impairment is subtle, transient, or subclinical, perioperative decline is associated with 5-year cognitive deterioration and reduced quality of life. multiple strategies, both clinical and pharmacological, have been proposed to reduce the central nervous system dysfunction associated with heart surgery. however, most strategies have been unsuccessful, met with limited success, or are unrealistic from a cost or risk-benefit ratio for the majority of people. this study will examine the effectiveness of supplemental magnesium at preventing the cognitive decline associated with heart surgery. design narrative: this study will examine the effect of supplemental magnesium on the neurocognitive function of individuals undergoing cabg surgery. the two hypotheses to be tested include the following: 1) therapeutic levels of magnesium reduce post-operative neurocognitive dysfunction after heart surgery; and 2) therapeutic magnesium levels protect quality of life through reduced cognitive dysfunction after heart surgery. this double-blind study will enroll 400 individuals and randomly assign them to either the treatment group, which will receive 100 mg/kg of magnesium, or to the control group. anesthesia management will be standardized to minimize any impact that anesthesia may have on neurologic or neuropsychologic outcome. neurocognitive testing will be conducted prior to surgery, and 6 weeks and 1 year following surgery.

Eligibility criteria:
inclusion criteria: * coronary heart disease exclusion criteria: * early dementia * history of psychiatric illness